Divalproex Sodium Tablet, Delayed Release
Product Images NDC 50090-7763

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-7763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Divalproex Sodium De Figure 1)

Chemical structure diagram of divalproex sodium, showing its molecular components and arrangement, including sodium ions and organic chains.*

FDA Label Image

Figure1 (Divalproex Sodium De Figure 2)

Bar chart comparing percentage outcomes between placebo (PBO) and divalproex sodium (DVPX) groups in two studies, Study 1 and Study 2, shown at yearly follow-up intervals (YMRS). The chart highlights higher percentages for DVPX in both studies.*

FDA Label Image

Figure2 (Divalproex Sodium De Figure 3)

A comparative line graph depicting the percentage reduction in CPS rate between divalproex sodium and placebo across a patient population. The y-axis shows percent reduction, ranging from worsening to improvement, and the x-axis shows percentage of patients, illustrating the efficacy distribution of the drug versus placebo.*

FDA Label Image

Figure3 (Divalproex Sodium De Figure 4)

A line graph showing the percentage reduction in CPS rate against the percentage of patients. The graph compares outcomes between high dose and low dose groups. The y-axis measures percent reduction in CPS rate from -100% to 100%, with annotations indicating 'Improvement' and 'No Change.' Two curves represent data trends for high and low doses respectively.*

FDA Label Image

Figure4 (Divalproex Sodium De Figure 5)

A bar graph comparing placebo and divalproex sodium across two studies labeled 'Study 1' and 'Study 2'. The graph shows numerical values on the vertical axis, with placebo bars higher than divalproex sodium bars in both studies, indicating a comparative measurement between the two groups.*

FDA Label Image

Label Image (Lbl500907763)

Label for divalproex sodium 250 mg delayed-release tablets from A-S Medication Solutions. The label includes the NDC 50090-7763-0, storage instructions to keep between 68 to 77 degrees Fahrenheit, and mentions that there are 30 tablets in the package. The label also notes that each coated, delayed-release tablet contains divalproex sodium equivalent to valproic acid 250 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.